RE:RE:RE:RE:RE:RE:Clarification from Fred.....Short term being 0-6 months for me I will be conservative and say no. But by the end of Q4 It's a YES And I believe that PLI's revenu forecast for 2017 should be met. 2018 will see a huge jump in revenue from PgCD. And I believe that we are finally coming to the point where every years following 2017 will see huge increase from the previous year and it should remain like this for many years. Once the market realize this fact then the anticipated value will also put pressure up on the SP.
However, I have no worry on liquidity as thomvest, even if they wont publicly say they are commited forever now (for strategic leverage reason for the next loan, cause yes they are still in the business of negociating the best loan terms for themself), they are our angel investor, and they know they will make a ton of money within the next 5 years.
also, maybe we will have a surprise faster BLA approval, but again, lets stay conservative and let's say that the FDA will take all there regulatory time and deliver the BLA at midnight by the end of september.
Everything is getting ready for a succesful launch of Pg for PgCD and I truely believe the off label use will also be a wild card on the amount of Pg sales as even if it is not reimburse at first by insurance, and legaly Prometic can't advertise it for other use than PgCD, I am sure that the word is going to spread fast that Prometic is in trial or considering trials for DFU, Burns, Tympanic, SRA-SDRA etc.
Since Pg will be sold to the 250 biggest and most specialized hospital in the USA, it means there will be a stock of Pg available in these hospital, the same hospital where they treat DFU, Severe burn SRA-SDRA etc. Even if it is not reimburse, I bet many patient would sell there car to treat there DFU or help a severe burn heal perfectly without leaving large scar and at a very fast speed (instead of 2-3 monts of hospitalisation).
Anyway, we will see in a couple of months.